The Chiba-Falek Lab at Duke University School of Medicine seeks a highly motivated postdoctoral research fellow to investigate genetic and epigenetic causes of Late Onset Alzheimer’s disease. The successful applicant will have a strong and productive scientific record, be highly collaborative, inquisitive, diligent, and have previous experience in one or more of the relevant fields: human genetics, neurobiology, functional genomics, molecular biology, RNA biology, and bioinformatics. Ideal candidates should be less than two years out from their Ph.D., and should demonstrate excellent verbal and written communication skills.
The Chiba-Falek Lab investigates genetic and molecular mechanisms controlling neurodegeneration and neuronal aging, and contributing to neurodegenerative pathologies and aged-related brain diseases. To tackle these questions, we employ genomic technologies, single-cell analyses of human brain tissues, iPSC-derived models, humanized mouse, bioinformatics tools, and genomic/epigenomic/transcriptomic datasets. The Chiba-Falek Lab has ongoing collaborations with labs at Duke as well as with other national and international investigators.
Our recent accomplishments include: discovery of structural variants and haplotype controlling gene expression and contributing to Lewy body dementia spectrum disorders (Lutz et al, Alzheimers Dement, 2015; Saul et al, Hum Mutat, 2016), discovery of miRNA-mediated mechanism contributing to the heterogeneity of synucleionopathies (Tagliafierro et al, Alzheimers Dement, 2017), identification of a transcription factor regulating genes associated with Alzheimer’s disease (Subramanian et al, Biochim Biophys Acta, 2017), development of single-cells based method for gene expression analysis (Tagliafierro et al, Front Mol Neurosci, 2016).
The primary goal for this position will be to investigate the underpinnings of how Alzheimer’s GWAS discoveries translate to disease causal mechanisms. The postdoctoral fellow will implement cutting-edge technologies in functional genomics, molecular profiling, single-cell analyses, and model systems, primarily iPSC gene-edited derived neurons. Additionally, the fellow will have the opportunity to pursue complementary projects in the lab at the intersection of molecular genetics and neurodegenerative diseases in aging. The lab and Department offer a vibrant and rigorous training environment for postdoctoral fellows.
Questions may be directed to Dr. Ornit Chiba-Falek at firstname.lastname@example.org
Applicants should submit a curriculum vitae, cover letter, a brief research statement, publication list, and contact information for 3 references to Dr. Ornit Chiba-Falek at email@example.com.
Duke University is an Affirmative Action/Equal Opportunity Employer committed to providing employment opportunity without regard to an individual's age, color, disability, gender, gender expression, gender identity, genetic information, national origin, race, religion, sex, sexual orientation, or veteran status. Duke also makes good faith efforts to recruit, hire, and promote qualified women, minorities, individuals with disabilities, and veterans.
Internal Number: 2018-10.OC.NJ
About Duke University School of Medicine
The Chiba-Falek Lab’s research focuses on the genetic factors and molecular mechanisms underlying age-related neurodegenerative diseases, in particular Alzheimer’s disease, related dementia, and Lewy body spectrum disorders. Our goal is to identify the precise causal and functional genetic variants underlying GWAS discoveries, and to understand their molecular mechanisms of action and the biological pathways through which they exert their pathogenic effects. To this end, we develop innovative in silico, in vitro, and in vivo approaches to study noncoding variants, specifically short structural variants, their corresponding trans factors, and their impact on the regulation of gene expression and splicing in the context of neurodegenerative phenotypes. Our research program has translational applications, informing clinical studies and supporting the development of novel genetic biomarkers and therapeutic targets.
--Developing isogenic iPSCs-derived model systems for studying the common and distinct genetic and molecular mechanisms underlying synucleinopathies
--Decoding the genetics of late-onset Alzheimer’s disease: From GWAS to functionally regulatory variants
--Structural... variants and neurodegenerative diseases in aging: regulatory and causality consequences
--Polymorphic repetitive sequences in the etiology of neurodegenerative disorders
--The broader contribution of SNCA gene to the wide spectrum of Lewy body disorders
--The Role of TOMM40-APOE genomic region in late onset Alzheimer’s disease